Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO)
CUSIP: 71880W501
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 12,067,869
- Total 13F shares
- 164,722
- Share change
- +64,104
- Total reported value
- $387,355
- Price per share
- $2.35
- Number of holders
- 11
- Value change
- +$164,978
- Number of buys
- 7
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 71880W501?
CUSIP 71880W501 identifies PHIO - Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 71880W501:
Top shareholders of PHIO - Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Gerrit Dispersyn |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
212,327
|
$320,614 | — | 01 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.34%
|
41,586
|
$54,060 | — | 31 Mar 2025 | |
| Cetera Investment Advisers |
13F
|
Company |
0.32%
|
38,500
|
$50,050 | — | 31 Mar 2025 | |
| H. Paul Dorman |
3/4/5
|
Director |
—
class O/S missing
|
20,370
|
$30,759 | — | 15 Feb 2022 | |
| XTX Topco Ltd |
13F
|
Company |
0.09%
|
10,800
|
$14,040 | — | 31 Mar 2025 | |
| Caitlin Kontulis |
3/4/5
|
Secretary & VP Finance & Admin |
—
class O/S missing
|
10,643
|
$10,196 | — | 01 Mar 2024 | |
| Robert M. Infarinato |
3/4/5
|
VP, CFO |
—
class O/S missing
|
11,000
|
$8,140 | — | 11 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.05%
|
6,000
|
$7,800 | — | 31 Mar 2025 | |
| Geert Cauwenbergh |
3/4/5
|
Director |
—
class O/S missing
|
4,235
|
$6,395 | — | 17 Feb 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
2,501
|
$3,251 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
968
|
$1,258 | — | 31 Mar 2025 | |
| ASSETMARK, INC |
13F
|
Company |
0%
|
110
|
$143 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
103
|
$134 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
41
|
$53 | — | 31 Mar 2025 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
9
|
$12 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
5
|
$7 | — | 31 Mar 2025 |
Institutional Holders of Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) as of Q2 2025
As of 30 Jun 2025,
Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
164,722 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Cetera Investment Advisers, Virtu Financial LLC, MORGAN STANLEY, Royal Bank of Canada, SBI Securities Co., Ltd., ASSETMARK, INC, BANK OF AMERICA CORP /DE/, and ELEVATION POINT WEALTH PARTNERS, LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
10
Q2 2025 holders
11
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.